Abstract
BACKGROUND: Pulse pressure variation (PPV) is unreliable in predicting fluid responsiveness (FR) in patients receiving mechanical ventilation with spontaneous breathing activity. Whether PPV can be valuable for predicting FR in patients with low inspiratory effort is unknown. We aimed to investigate whether PPV can be valuable in patients with low inspiratory effort. METHODS: This prospective study was conducted in an intensive care unit at a university hospital and included acute circulatory failure patients receiving volume-controlled ventilation with spontaneous breathing activity. Hemodynamic measurements were collected before and after a fluid challenge. The degree of inspiratory effort was assessed using airway occlusion pressure (P(0.1)) and airway pressure swing during a whole breath occlusion (ΔP(occ)) before fluid challenge. Patients were classified as fluid responders if their cardiac output increased by ≥ 10%. Areas under receiver operating characteristic (AUROC) curves and gray zone approach were used to assess the predictive performance of PPV. RESULTS: Among the 189 included patients, 53 (28.0%) were defined as responders. A PPV > 9.5% enabled to predict FR with an AUROC of 0.79 (0.67-0.83) in the whole population. The predictive performance of PPV differed significantly in groups stratified by the median value of P(0.1) (P(0.1) < 1.5 cmH(2)O and P(0.1) ≥ 1.5 cmH(2)O), but not in groups stratified by the median value of ΔP(occ) (ΔP(occ) < - 9.8 cmH(2)O and ΔP(occ) ≥ - 9.8 cmH(2)O). Specifically, in patients with P(0.1) < 1.5 cmH(2)O, PPV was associated with an AUROC of 0.90 (0.82-0.99) compared with 0.68 (0.57-0.79) otherwise (p = 0.0016). The cut-off values of PPV were 10.5% and 9.5%, respectively. Besides, patients with P(0.1) < 1.5 cmH(2)O had a narrow gray zone (10.5-11.5%) compared to patients with P(0.1) ≥ 1.5 cmH(2)O (8.5-16.5%). CONCLUSIONS: PPV is reliable in predicting FR in patients who received controlled ventilation with low spontaneous effort, defined as P(0.1) < 1.5 cmH(2)O. Trial registration NCT04802668. Registered 6 February 2021, https://clinicaltrials.gov/ct2/show/record/NCT04802668.